Leica Biosystems introduces ChromoPlex III detection system for streamlined multiplex immunohistochemistry
Newcastle-based Leica Biosystems has launched ChromoPlex III Triple Detection RUO, a chromogenic multiplex immunohistochemistry detection system designed to simplify assay workflows whilst enhancing reproducibility for digital pathology applications. The research-use-only system addresses growing demand for accessible multiplex IHC tools in spatial biology research and tumour microenvironment characterisation.
Plug-and-play format eliminates complex preparation steps
ChromoPlex III’s streamlined design removes the need for antibody conjugation, offering researchers a simplified workflow where antibodies are selected, chromogen colours assigned (brown, red, or green), and the kit loaded directly onto BOND RX or RXm stainer platforms. Pre-optimised reagents and protocols minimise setup variability whilst maintaining consistent staining quality. “ChromoPlex III is built to meet the evolving needs of researchers working at the intersection of spatial biology and computational pathology,” said Karan Arora, Senior Vice President of Advanced Assays, Pharma Services, and AI at Leica Biosystems. “Its chromogenic format mirrors clinical diagnostics, allowing researchers and pathologists to visualise tissue architecture while producing reproducible results that are essential for image analysis and AI interpretation.”
Digital-ready staining optimised for computational analysis
The system integrates seamlessly within Leica Biosystems’ translational research ecosystem, enabling users to stain on BOND RX, scan with Aperio systems, and analyse with HALO software. This end-to-end compatibility addresses the specific requirements of high-resolution digital imaging and computational pathology workflows, providing consistent chromogenic staining optimised for artificial intelligence interpretation.
ChromoPlex III’s chromogenic approach maintains visual compatibility with traditional diagnostic practices whilst delivering the quantifiable, reproducible data essential for advanced image analysis algorithms. The system supports researchers developing precision medicine approaches through enhanced spatial biology characterisation capabilities.
Strategic positioning for cancer research advancement
“The launch of ChromoPlex III underscores Leica Biosystems’ commitment to accelerating cancer research and advancing the future of diagnostics and therapies,” said Gustavo Perez, President at Leica Biosystems. “By combining ease of use with digital compatibility, ChromoPlex III helps researchers generate high-resolution, quantifiable data to support the development of more precise and personalised treatment strategies.”
The system is available immediately for research applications, with an interactive image gallery showcasing whole slide images demonstrating the technology’s staining consistency and digital analysis compatibility.
For more information, visit: https://shop.leicabiosystems.com/us/ihc-ish/detection-systems/pid-chromoplex-iii-triple-detection-ruo
Digital issue: Please click here for more information
